Risankizumab is Superior to Placebo for Induction and Maintenance of Moderate-Severe Ulcerative Colitis (UC): Assessing the UC Treatment Paradigm

Philip Schoenfeld, MD, MSEd, MSc (Epi) and Rahul Dalal, MD, MPH discuss “Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials,” by Louis E, Schreiber S, Panaccione R, Bossuyt P, et al for the INSPIRE and COMMAND Study Group. JAMA. 2024 Jul 22:e2412414